Opinion|Videos|January 21, 2025
Overcoming Barriers to Biomarker Testing in Unresectable NSCLC: Strategies for Improved Access and Implementation
This segment discusses the importance of biomarker testing in lung cancer, challenges in implementation such as tissue adequacy and result delays, and strategies to enhance testing in both academic and community settings through local champions and education.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some barriers you encounter with biomarker testing in NSCLC?
- Do you have any thoughts on how to expand appropriate testing, particularly in the community setting?
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
3
CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC
4
Dr Gilbert on the Efficacy of Relacorilant Plus Nab-Paclitaxel in Ovarian Cancer
5